Bleeding incidence with concomitant use of antidepressants and warfarin

Therapeutic Drug Monitoring

Volumn 33, Issue 4, 2011, Pages 433-438

  Cochran, Kelly A ^a   Cavallari, Larisa H ^b   Shapiro, Nancy L ^b   Bishop, Jeffrey R ^b,c  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c MC 886 ^*  (United States)

Author keywords

Anticoagulation; Antidepressant; Bleeding; SSRI; Warfarin

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CREATININE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; WARFARIN;

ADULT; ARTICLE; BLEEDING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; EAR DISEASE; EAR HEMORRHAGE; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENITOURINARY BLEEDING; GINGIVA BLEEDING; HEART INFARCTION; HEMATOMA; HEMORRHOID HEMORRHAGE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STROKE; UROGENITAL TRACT DISEASE;

ANTICOAGULANTS; ANTIDEPRESSIVE AGENTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; WARFARIN;

EID: 80051787099     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318224996e     Document Type: Article

References (35)

1. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:257S-298S. (Pubitemid 351892969)
2. BMS. Coumadin Prescribing Information. Princeton, NJ: Bristol-Meyers Squibb; 2010.
3. Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;163:59-64. (Pubitemid 36091601)
4. de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319:1106-1109. (Pubitemid 29494721)
5. Meijer WE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med. 2004;164:2367-2370. (Pubitemid 39532249)
6. Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol. 2008;66:76-81. (Pubitemid 351822152)
7. Ottervanger JP, Stricker BH, Huls J, et al. Bleeding attributed to the intake of paroxetine. Am J Psychiatry. 1994;151:781-782.
8. Sarma A, Horne MK 3rd. Venlafaxine-induced ecchymoses and impaired platelet aggregation. Eur J Haematol. 2006;77:533-537. (Pubitemid 44690802)
9. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics. 1996;37:12-16. (Pubitemid 26021814)
10. Tata LJ, Fortun PJ, Hubbard RB, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther. 2005;22:175-181. (Pubitemid 41153059)
11. van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001;323:655-658. (Pubitemid 32897004)
12. Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther. 2006;23:937-944.
13. Andersohn F, Konzen C, Bronder E, et al. Citalopram-induced bleeding due to severe thrombocytopenia. Psychosomatics. 2009;50:297-298.
14. Abdelmalik N, Ruhe HG, Barwari K, et al. Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. J Thromb Haemost. 2008;6:2168-2174.
15. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost. 2004;91:119-128. (Pubitemid 38120206)
16. Serebruany VL, Gurbel PA, O'Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res. 2001;43:453-462.
17. Ataoglu A, Canan F. Mean platelet volume in patients with major depression: effect of escitalopram treatment. J Clin Psychopharmacol. 2009;29:368-371.
18. Schalekamp T, Klungel OH, Souverein PC, et al. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med. 2008;168:180-185. (Pubitemid 351185885)
19. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91-99. (Pubitemid 28405230)
20. Kuijer PM, Hutten BA, Prins MH, et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999;159:457-460. (Pubitemid 29108910)
21. Duncan D, Sayal K, McConnell H, et al. Antidepressant interactions with warfarin. Int Clin Psychopharmacol. 1998;13:87-94. (Pubitemid 28218520)
22. Glueck CJ, Khalil Q, Winiarska M, et al. Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio. JAMA. 2006;295:1517-1518.
23. Hauta-Aho M, Tirkkonen T, Vahlberg T, et al. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med. 2009;41:619-628.
24. Wallerstedt SM, Gleerup H, Sundstrom A, et al. Risk of clinically relevant bleeding in warfarin-treated patients-influence of SSRI treatment. Pharmacoepidemiol Drug Saf. 2009;18:412-416.
25. Kurdyak PA, Juurlink DN, Kopp A, et al. Antidepressants, warfarin, and the risk of hemorrhage. J Clin Psychopharmacol. 2005;25:561-564. (Pubitemid 41669050)
26. Kharofa J, Sekar P, Haverbusch M, et al. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke. 2007;38:3049-3051. (Pubitemid 350035702)
27. Musselman DL, Marzec UM, Manatunga A, et al. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry. 2000;57:875-882.
28. Kaminsky LS, de Morais SM, Faletto MB, et al. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol. 1993;43:234-239. (Pubitemid 23055067)
29. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:160S-S198.
30. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897-902. (Pubitemid 24179151)
31. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315-328. (Pubitemid 23270290)
32. Kessler RC. Epidemiology of women and depression. J Affect Disord. 2003;74:5-13. (Pubitemid 36329172)
33. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105. (Pubitemid 37432885)
34. Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol. 2009;104:1475-1482.
35. Robinson RG, Spalletta G. Poststroke depression: a review. Can J Psychiatry. 55:341-349.